Circulating zinc-α2-glycoprotein levels are low in newly diagnosed patients with metabolic syndrome and correlate with adiponectin
Open Access
- 14 August 2017
- journal article
- research article
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 14 (1) , 1-7
Abstract
Zinc-α2-glycoprotein (ZAG) is a novel adipokine that reduces insulin resistance, protecting against type 2 diabetes. However, past studies have been contradictory. This cross-sectional study aims to investigate the association of circulating ZAG with metabolic syndrome (MetS) in middle-aged and older Chinese adults. Four hundred eighty nine individuals (234 healthy controls and 255 MetS patients) were examined. All individuals were screened for MetS according to the diagnostic guidelines of the United States National Cholesterol Education Program (NCEP) Expert Panel Adult Treatment Panel (ATP) III criteria. Circulating ZAG and ADI levels were measured by ELISA. Blood fat, glucose and insulin were measured with a commercial kit. Circulating ZAG levels were compared with various parameters in study subjects. Plasma ZAG levels were lower in MetS patients compared to those of the healthy controls (35.0 ± 11.7 vs. 46.1 ± 18.6 mg/L, P < 0.01). ZAG showed a positive correlation with age, HDL-C, HOMA-β and ADI, but a negative correlation with Fat%, BMI, WHR, blood pressure, triglycerides, FFA, FBG, 2 h–BG, fasting insulin, 2 h–Ins, HbA1c and HOMA-IR (P < 0.01). When the population was divided according to tertiles of ADI, subjects in the highest tertile had the highest ZAG levels. The analysis of ROC curves revealed that the best cutoff value for plasma ZAG to predict MetS was 45.2 mg/L (sensitivity 92%, specificity 59%, and AUC 0.80). We found that circulating ZAG levels were decreased in patients with MetS. In fact, circulating ZAG decreased progressively with an increasing number of MetS components and associated with ADI levels, suggesting that ZAG is related to IR and MetS and may be a sensitizer. ChiCTR-OCC-11001422 . Registered 23 June 2011.Keywords
Funding Information
- the Natural Science Foundation Project of CQ andthe Science and Technology Key Program of Health Bureau of Chongqing (No. cstc2015jcyjA10084 and2015ZDXM038)
This publication has 19 references indexed in Scilit:
- Zinc-α2-Glycoprotein Is Associated With Insulin Resistance in Humans and Is Regulated by Hyperglycemia, Hyperinsulinemia, or Liraglutide AdministrationDiabetes Care, 2013
- Low serum osteocalcin level is a potential marker for metabolic syndrome: results from a Chinese male population surveyMetabolism, 2011
- Lipolysis is altered in MHC class I zinc‐α2‐glycoprotein deficient miceFEBS Letters, 2007
- Polymorphisms of the gene encoding adiponectin and glycaemic outcome of Chinese subjects with impaired glucose tolerance: a 5-year follow-up studyDiabetologia, 2006
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexiaProceedings of the National Academy of Sciences, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance testDiabetologia, 2000
- Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues.Journal of Histochemistry & Cytochemistry, 1991
- Role of Insulin Resistance in Human DiseaseDiabetes, 1988